HTB

HIV prevention and transmission

No transmission of integrase-resistant HIV seen in California cohort

The PrEP experience: IAS 2015 and beyond

i-Base Q&A resources on PrEP: increased use of off-label PrEP in the UK shows need for NHS support and risk to PEP services

Two new UK community PrEP websites

First UK NHS PrEP support service launched at 56 Dean Street, Soho

UK PROUD study published as open access article in The Lancet: PrEP dramatically reduces risk of HIV

Four reasons IAS 2015 will be a milestone HIV conference: a personal view

HPTN 052: no HIV transmissions on effective ART but only limited data on viral failure and drug resistance

Rectal STIs and viral load in HIV positive men on and off ART

Methmephangee – ChemSex vs recreational drug use: a proposed definition for health workers

No HIV transmissions between gay couples when viral load is undetectable: preliminary results from “Opposites Attract” study in Australia, Thailand and Brazil

PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds

“On demand” PrEP dosing in IPERGAY: 86% reduced risk of HIV, no transmissions with active drug use

Other HIV PrEP studies at CROI 2015: implementation of oral PrEP and problems with tenofovir gel

HIV prevention budget for 2015 slashed by 50%, then rapidly reinstated

Grassroots demand grows for early access to PrEP in the UK

New York announces new policy to dramatically reduce HIV incidence by 2020

UK PROUD study to provide PrEP to all participants earlier than expected: planned follow-up to continue to two years

IPERGAY PrEP study shows early efficacy in protecting gay men from HIV: all participants to switch to active drug

HIV in the UK 2014: Public Health England report on incidence and care

UK PROUD study to provide PrEP earlier than expected: planned follow-up to continue to two years

Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP

Update on baseline STIs in UK oral PrEP study (PROUD)

HIV reinfection has limited impact on disease progression

Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

Open label oral PrEP at four doses a week: why zero infections does not equal 100% efficacy

Preventive technologies: antiretroviral and vaccine development

No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up

PrEP injections every three months may protect against exposure from anal sex

The little blue pill that can stop HIV: PROUD study enrolling gay men in the UK

Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive

HIV self testing to become legal in the UK from April 2014

Agreement to develop long-acting rilpivirine as PrEP

Use of ART at baseline by treatment naïve patients in HPTN-052

Partner-dependent immune differences may protect against HIV infection

Bangkok Tenofovir Study: US CDC recommends oral PrEP for injecting drug users – based on 16 fewer infections over 5 years

Preventive technologies, research toward a cure, and immune-based and gene therapies

Monthly injection protects macaques from rectal exposure: results should fast-track human studies for advanced PrEP options

Tenofovir DF ring protects macaques from vaginal exposure

VOICE study reports low adherence as reason for lack of efficacy for PrEP: anal sex common in African heterosexuals

Further studies on how male circumcision may reduce HIV transmission

Minimal risk of sexual HIV transmission for heterosexual couples when the HIV positive partner has an undetectable viral load

UK group describe risk of HIV transmission for people on effective ART as “extremely low”

CDC issues brief on the prevention benefits of HIV treatment

WHO recommendations for prevention and treatment of HIV for sex workers and their clients

Quantifying HIV-1 exposure to illuminate resistance to infection

Immune activation, inflammation and HIV acquisition risk

HPTN-052: clinical advantages from earlier treatment

Online video interviews between researchers and activists

High levels of maraviroc in rectal tissue fail to protect macaques from SIV transmission following rectal exposure

Mechanisms for circumcision to reduce HIV transmission in different penile tissue: target cell differences rather than keratinisation

FDA approve Truvada to reduce the risk of sexual transmission

Half of gay men in London would chose oral PrEP to reduce risk of HIV

Recent infection is common in UK; 30% gay men aged 15-25 infected within a year of diagnosis

3rd vs 4th generation HIV testing: almost half of UK clinics out of step with national guidelines

WHO guidelines for testing, counselling and treatment in serodifferent couples (April 2012): ART at CD4 >350 to reduce transmission

NICE guideline on fertility treatment proposes alternatives to sperm washing (2012)

Early data for rilpivirine long acting formulation supports further investigation for PrEP

PrEP: PK modeling of daily TDF/FTC (Truvada) provides close to 100% protection against HIV infection

Risk of HIV reinfection may be similar to risk of initial HIV infection

Case report: homozygous CCR5 delta-32 protection overcome by infection with X4 virus

NICE guidance on increasing the uptake of HIV testing

International PrEP study (VOICE) discontinues use of tenofovir vaginal gel due to lack of efficacy

UK Health Protection Agency (HPA) recommends universal HIV testing in the high incidence regions of the UK

Orange Farm circumcision results dispel concerns about risk compensation

Post navigation